表紙
市場調査レポート

Concert Pharmaceuticals, Inc. - 商品パイプラインレビュー

Concert Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224659
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Concert Pharmaceuticals, Inc. - 商品パイプラインレビュー Concert Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 34 Pages
概要

Concert Pharmaceuticals, Inc. 重水素物質プラットフォームを活用した新しい薬剤を開発し、様々な疾患に適用している製薬会社です。同社製品の治療対象は、糖尿病性腎臓疾患や、神経性障害、精神性障害などの他、多岐に渡ります。

当レポートでは、Concert Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Concert Pharmaceuticals, Inc.の基本情報

  • Concert Pharmaceuticals, Inc.の概要
  • 主要情報
  • 企業情報

Concert Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Concert Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Concert Pharmaceuticals, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Concert Pharmaceuticals, Inc.:薬剤プロファイル

  • CTP-499
  • CTP-354
  • C-10068
  • CTP-221
  • D-Ivacaftor
  • D-Praziquantel
  • C-10291

Concert Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Concert Pharmaceuticals, Inc.:最近のパイプライン動向

Concert Pharmaceuticals, Inc.:休止中のプロジェクト

Concert Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07711CDB

Summary

Global Markets Direct's, 'Concert Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Concert Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Concert Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Concert Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Concert Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Concert Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Concert Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Concert Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Concert Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Concert Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Concert Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Concert Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Concert Pharmaceuticals, Inc. Snapshot
    • Concert Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Concert Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Concert Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Concert Pharmaceuticals, Inc. - Pipeline Products Glance
    • Concert Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Concert Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Concert Pharmaceuticals, Inc. - Drug Profiles
    • CTP-499
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-10355
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-10358
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-354
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-656
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTP-221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • D-Praziquantel
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Concert Pharmaceuticals, Inc. - Pipeline Analysis
    • Concert Pharmaceuticals, Inc. - Pipeline Products by Target
    • Concert Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Concert Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Concert Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Concert Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Concert Pharmaceuticals, Inc. - Dormant Projects
  • Concert Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Concert Pharmaceuticals, Inc., Key Information
  • Concert Pharmaceuticals, Inc., Key Facts
  • Concert Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Concert Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Concert Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Concert Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Concert Pharmaceuticals, Inc. - Phase II, 2015
  • Concert Pharmaceuticals, Inc. - Phase I, 2015
  • Concert Pharmaceuticals, Inc. - Preclinical, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Concert Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Concert Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Concert Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Concert Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Concert Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Concert Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top